Stocks Health care NAMS
NASDAQ · Health careNewAmsterdam Pharma Co N.V. (NAMS)
NewAmsterdam Pharma Co N.V. brought in $25.9M of revenue over the twelve months to September 30, 2026, down 26.4% from a year earlier. It posted a net loss of $204.9M. In fiscal 2025 capital spending exceeded operating cash flow by $148M. At September 30, 2026 it held $423.1M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 4, 2026.
Key facts about NewAmsterdam Pharma Co N.V.
- Net worth
- NewAmsterdam Pharma Co N.V. has a market value (market cap) of $2.3B at the latest share price, and shareholders' equity of $630.8M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $22.5M (-50.6% year on year), with a net loss of $203.8M. Over the 12 months to September 30, 2026: revenue $25.9M, net loss $204.9M.
- Cash flow
- In fiscal 2025 operations used $147.8M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 4, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- NewAmsterdam Pharma Co N.V.'s next report was expected around November 4, 2026 and is not on file with the SEC yet.
What NewAmsterdam Pharma Co N.V. does
NewAmsterdam Pharma Co N.V. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker NAMS.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $22.5M | -$203.8M | -$1.72 | -$148M |
| 2024 | $45.6M | -$241.6M | -$2.56 | -$159.2M |
| 2023 | $14.1M | -$176.9M | -$2.15 | -$141.2M |
| 2023 | $102.7M | -$22.6M | -$1.19 | $10.4M |
| 2021 | n/a | -$41.8M | -$3.81 | -$29.5M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where NAMS ranks in Health care
Latest SEC filings
What NewAmsterdam Pharma Co N.V. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026Passive stake changed SCHEDULE 13G/A
- November 4, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 5,407% to $19.2M versus the same quarter last year; diluted EPS -$0.14 versus -$0.61.
- November 4, 2026Exhibits 8-K
- September 29, 2026Other event 8-K
- September 22, 2026Activist stake changed SCHEDULE 13D/A
- September 21, 2026Other event 8-K
- August 14, 2026
- August 14, 2026
- August 6, 2026Passive stake changed SCHEDULE 13G/A
- August 5, 2026
Insider trades
What the people running NewAmsterdam Pharma Co N.V. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $226.5K and sold $4.7M worth of shares in the last 90 days. Most of the selling (99%) was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 30, 2026 | Kastelein Johannes Jacob PieterChief Scientific Officer, Director | Exercised optionsindirect | 50,246 | - |
| September 30, 2026 | Kastelein Johannes Jacob PieterChief Scientific Officer, Director | Soldpre-planned (10b5-1), indirect | 50,246 | $1.3M |
| September 14, 2026 | Davidson Michael H.Chief Executive Officer, Director | Bought | 10,000 | $226.5K |
| September 4, 2026 | Smither John WDirector | Sold | 1,600 | $40.5K |
| September 1, 2026 | Gunning Robert WilliamVice President, Controller | Received as pay | 3,200 | - |
| August 24, 2026 | Kastelein Johannes Jacob PieterChief Scientific Officer, Director | Exercised optionsindirect | 125,000 | - |
| August 24, 2026 | Kastelein Johannes Jacob PieterChief Scientific Officer, Director | Soldpre-planned (10b5-1), indirect | 125,000 | $3.4M |
| July 20, 2026 | Kooij Louise FrederikaChief Accounting Officer | Exercised options | 25,000 | $297.5K |
Who owns NAMS
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| James N. Topper13D, may seek influence with 17 related filers | 15.3% | December 17, 2024 |
| Capital World Investors13G, passive | 10.4% | June 4, 2026 |
| RA Capital Management, L.P.13G, passive with 3 related filers | 9.9% | May 15, 2025 |
| Fmr LLC13G, passive with 1 related filers | 8.8% | August 6, 2026 |
| Frazier Life Sciences Public Fund, L.P.13D, may seek influence with 14 related filers | 8.7% | September 22, 2026 |
| ForGrowth NAP B.V.13D, may seek influence with 4 related filers | 8.3% | September 30, 2025 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 195 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Frazier Life Sciences Management, L.P. | 18,088,902 | +1,145,128 |
| Capital World Investors | 12,230,557 | +1,121,523 |
| Fmr LLC | 10,339,663 | +1,573,852 |
| RA Capital Management, L.P. | 9,550,191 | 0 |
| Fcpm III Services B.V. | 8,490,353 | -708,547 |
| Deerfield Management Company, L.P. | 4,264,789 | 0 |
| Viking Global Investors LP | 4,203,567 | 0 |
| Bain Capital Life Sciences Investors, LLC | 3,806,566 | -3,500,000 |
| Maverick Capital Ltd | 3,267,802 | +1,081,400 |
| Jupiter Topco LLC | 2,535,682 | new |
| Medicxi Ventures Management (Jersey) Ltd | 2,208,639 | -465,543 |
| Jennison Associates LLC | 2,102,286 | -648,117 |
| Orbis Allan Gray Ltd | 1,747,627 | new |
| Polar Capital Holdings Plc | 1,724,518 | -1,107,089 |
| Capital International Investors | 1,723,495 | +282,364 |
| Goldman Sachs Group Inc | 1,544,911 | -401,463 |
| Westfield Capital Management Co LP | 1,536,472 | -666,441 |
| Castle Hook Partners LP | 1,371,005 | +328,368 |
| Ameriprise Financial Inc | 1,253,549 | +500,495 |
| Alliancebernstein L.P. | 1,259,940 | +60,615 |
Insiders
11 insiders reported holding 1,066,120 shares in total, about $20.3M at the last price.
| Holder | Shares |
|---|---|
| Davidson Michael H.Chief Executive Officer, Director | 792,923 |
| Kastelein Johannes Jacob PieterChief Scientific Officer, Director | 122,80269,302 held indirectly |
| Somaiya Mayur IanChief Financial Officer | 58,382 |
| Kooij Louise FrederikaChief Accounting Officer | 24,353 |
| Gulfo Adele M.Director | 14,260 |
| Lange Louis GDirector | 10,360 |
| Lewis WilliamDirector | 10,360 |
| McKenna Mark C.Director | 10,360 |
| van der Kamp Hilde JohannaDirector | 10,360 |
| Smither John WDirector | 8,760 |
Questions about NAMS
What does NewAmsterdam Pharma Co N.V. do?
NewAmsterdam Pharma Co N.V. is a company in the Health care sector, listed on NASDAQ as NAMS. Its shares trade on NASDAQ under the ticker NAMS.
What is NewAmsterdam Pharma Co N.V.'s net worth?
NewAmsterdam Pharma Co N.V. has a market value (market cap) of $2.3B at the latest share price, and shareholders' equity of $630.8M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is NewAmsterdam Pharma Co N.V. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $204.9M on revenue of $25.9M.
How much revenue does NewAmsterdam Pharma Co N.V. make?
Over the twelve months to September 30, 2026 NewAmsterdam Pharma Co N.V. reported revenue of $25.9M. That is 26.4% less than a year earlier.
When did NewAmsterdam Pharma Co N.V. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 4, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the passive stake changed from November 5, 2026.
When is NewAmsterdam Pharma Co N.V.'s next earnings report?
NewAmsterdam Pharma Co N.V.'s next report was expected around November 4, 2026 and is not on file with the SEC yet.
Similar companies
Compare NAMS with
Follow NAMS
Get an email when NewAmsterdam Pharma Co N.V. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values NewAmsterdam Pharma Co N.V. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.